Accolade

Accolade, Inc. engages in the provision of personalized health and benefits solutions. Its products include Accolade Total Benefits, which is designed for employers with low employee adoption of healthcare and benefits programs, Accolade Total Care, which focuses on influencing the actual interactions between employees and providers, and are also interested in care management services, and Accolade Total Health and Benefits, which offers a full suite of solutions. The company was founded by Thomas K. Spann, J. Michael Cline, and Sudhir Steven Singh in 2007 and is headquartered in Seattle, WA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Accolade reports strong Q4 performance, faces market challenges ahead

Accolade's transformation into a personalized healthcare company has shown strong growth and improved financial performance. The company faces challenges related to operational excellence, market strategy, and the impact of industry decisions. However, opportunities lie in leveraging technology for healthcare and the upcoming Capital Markets Day to showcase growth prospects.

Accolade exceeds Q3 revenue guidance, eyes profitability by fiscal '25

Accolade's Q3 earnings call highlighted strong performance, diverse customer relationships, and growth opportunities in government business and virtual care. The company aims to achieve profitability by fiscal '25 through strategic investments and operational improvements, leveraging its competitive advantage in delivering ROI and performance guarantees.

Accolade reports robust Q4 performance, eyes tech-driven growth opportunities

Accolade's Q4 2023 Earnings Call highlighted strong financial performance, customer focus, and strategic initiatives. The company faces challenges in timing performance guarantees but sees opportunities in technology adoption and growth strategies.

Accolade surpasses Q1 expectations, eyes growth in healthcare partnerships

Accolade's Q1 performance exceeded expectations, with a focus on growth drivers and streamlining decision-making. Despite challenges in the government business, the company is optimistic about future growth opportunities and customer acquisition. Improved guidance and a strong pipeline indicate a positive outlook for the year.

Accolade beats Q2 revenue targets, eyes profitability in fiscal '25

Accolade exceeded revenue and EBITDA expectations in Q2, driven by strong customer additions and unique service offerings. Despite challenges from drug impacts and contract disputes, the company maintains its full-year guidance and eyes profitability in fiscal '25.

Accolade excels in Q3, eyes automation for growth opportunities

Accolade's Q3 performance exceeded expectations, with a positive outlook for future revenue and EBITDA. Differentiation in services and technology integration drive operational excellence. Uncertainty around TRICARE contract and focus on automation and growth opportunities.

Accolade reports robust Q4 earnings, eyes sustainable growth in '25

Accolade's strong performance in Q4 2024 sets a positive trajectory for fiscal year '25, with a focus on sustainable growth and profitability. The company's strategic strengths in serving a large customer base, successful partnerships, and innovative offerings position it well for future opportunities despite challenges in meeting revenue guidance and addressing post-security breach concerns.

Accolade reports strong Q2 earnings, focuses on profitability and growth

Accolade's Q2 performance exceeded expectations, emphasizing profitability and member experience.
The company's strengths lie in revenue growth, cost management, and competitive wins.
Challenges include cost structure management and balancing growth with profitability.
Opportunities exist in enhancing member experience, expanding partnerships, and driving sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann and J. Michael Cline in January 2007 and is headquartered in Seattle, WA.

Accolade, Inc. (NASDAQ:ACCD ) Q3 2023 Earnings Conference Call January 9, 2023 4:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of Investor Relations Conference Call Participants Michael Cherny - Bank of America Ryan Daniels - William Blair & Company Cindy Motz - Goldman Sachs Craig Hettenbach - Morgan Stanley Glen Santangelo - Jefferies Jonathan Yong - Credit Suisse William Hoover - Canaccord Genuity Jailendra Singh - Truist Ryan MacDonald - Needham Jessica Tassan - Piper Sandler. Stephanie Davis - SVB Securities Stanislav Berenshteyn - Wells Fargo Robert Simmons - D.A.

Accolade, Inc. (ACCD) Q3 2023 Earnings Call Transcript

Accolade (ACCD) delivered earnings and revenue surprises of 8.20% and 4.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?

Accolade (ACCD) Reports Q3 Loss, Tops Revenue Estimates

SEATTLE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal third quarter ended November 30, 2022.

Accolade Announces Results for Fiscal Third Quarter 2023

SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the 25th Annual Needham Growth Conference on Wednesday, January 11, 2023 and will host a fireside chat at 1:30 pm ET. A webcast and replay of the fireside chat will be available at ir.accolade.com.

Accolade Announces Participation in 25th Annual Needham Growth Conference

SEATTLE, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal third quarter 2023 financial results on Monday, January 9, 2023, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Accolade to Announce Fiscal Third Quarter 2023 Financial Results

Chief Medical Officer Dr. Shantanu Nundy and Dr. Jay Bhatt, Managing Director at Deloitte, explore the role of employers in removing barriers to equitable healthcare; Accolade welcomes a new trusted partner serving LGBTQIA+ communities and marks the 3-year anniversary of the Trusted Partner Ecosystem SEATTLE , Nov. 14, 2022 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD), which provides millions of people and their families with Personalized Healthcare, will address removing barriers to equitable healthcare as a Health Equity Impact Champion sponsor at HLTH 2022. In addition, LGBTQIA+ affirming care company, FOLX Health, joins Accolade's Trusted Partner Ecosystem, availing high-quality, integrated care for this marginalized population to Accolade 's 700+ commercial and government customers to serve their 11 million members.

Accolade Champions Health Equity and Welcomes FOLX Health to Trusted Partner Ecosystem at HLTH 2022

Accolade Inc. (NASDAQ:ACCD ) Q2 2023 Earnings Conference Call October 6, 2022 4:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of Investor Relations Conference Call Participants Michael Cherny - Bank of America Glen Santangelo - Jeffries Jonathan Yong - Credit Suisse Jailendra Singh - Truist Cindy Motz - Goldman Sachs Craig Hettenbach - Morgan Stanley Stephanie Davis - SVB Securities Richard Close - Canaccord Genuity. Stanislav Berenshteyn - Wells Fargo Dev Weerasuriya - Berenberg.

Accolade Inc. (ACCD) Q2 2023 Results - Earnings Call Transcript

SEATTLE, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August 31, 2022.

Accolade Announces Results for Fiscal Second Quarter 2023

Accolade (ACCD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accolade (ACCD) Expected to Beat Earnings Estimates: Should You Buy?

SEATTLE, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal second quarter 2023 financial results on Thursday, October 6, 2022, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Accolade to Announce Fiscal Second Quarter 2023 Financial Results

Carrum's Value-Based Centers of Excellence Solution Now Easily Accessible to Accolade Clients for More Affordable, Appropriate Surgical Care SAN FRANCISCO , Aug. 17, 2022 /PRNewswire/ -- Carrum Health , the first digital health company connecting employers and employees to Centers of Excellence (COEs) through a technology-powered platform focused on delivering value-based care, today announced a partnership with Accolade (Nasdaq: ACCD) to deliver a fully integrated healthcare experience with proven cost savings and improved care outcomes. Accolade clients can now easily activate Carrum's value-based COE program through their existing contract and quickly offer their employees access to personalized guidance and treatment from best-in-class providers that have been rigorously evaluated and selected using industry-leading quality algorithms.

Carrum Health Selected as Trusted Partner by Accolade to Help Employers Achieve Immediate and Tangible Cost Savings

With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE , July 25, 2022 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity engagements for multiple Fortune 500 companies, will lead Accolade's information security business unit and support the overall compliance and risk management function, enhancing its information security and privacy posture to support growth and protect the trust of Accolade's customers and members.

Accolade appoints new chief information security officer

GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Priority Health, a nationally recognized nonprofit health plan, announced today the launch of PriorityGPS™, an integrated health navigation and advocacy solution. PriorityGPS will be delivered through a strategic partnership with Accolade (Nasdaq: ACCD), a Personalized Healthcare service, and is available for self-funded (ASO), large employers. According to a survey conducted by the International Federation of Employee Benefit Plans, about half of employees

Priority Health announces launch of new health navigation solution, PriorityGPS™

Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ: ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in 1QF23 as the company beat management's initial outlook for.

Here's Why Accolade Shares Are Trading Higher Today

Accolade (NASDAQ: ACCD) is certainly an interesting play on the health care space providing business and employee services geared toward helping clients navigate the cumbersome health benefits arena. The pandemic helped boost the company's business and has on track to continue growing but there is a fly in the ointment.

Accolade Moves Higher But Growth Is Slowing

Akebia Therapeutics

Micron Technology

Costco

Hillenbrand

Some of the stocks that may grab investor focus today are: Micron Technology Inc (NASDAQ: MU) reported upbeat financial results for its third quarter, but issued weak guidance for its fourth quarter. Micron shares dropped 1.4% to $54.50 in the after-hours trading session.

Micron, Akebia Therapeutics And 3 Stocks To Watch Heading Into Friday

Accolade, Inc. (NASDAQ:ACCD ) Q1 2023 Earnings Conference Call June 30, 2022 4:30 PM ET Company Representatives Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior Vice President of Investor Relations Conference Call Participants Ryan Daniels - William Blair Glen Santangelo - Jefferies Richard Close - Canaccord Genuity Michael Cherny - Bank of America. Cindy Motz - Goldman Sachs Jonathan Yong - Credit Suisse Craig Hettenbach - Morgan Stanley Jeff Garro - Piper Sandler David Larsen - BTIG Ryan MacDonald - Needham Stephanie Davis - SVB Securities Stan Berenshteyn - Wells Fargo Dev Weerasuriya - Berenberg Sandy Draper - Guggenheim Operator Good day!

Accolade, Inc. (ACCD) CEO Rajeev Singh on Q1 2023 Results - Earnings Call Transcript

SEATTLE, June 30, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2022.

Accolade Announces Results for Fiscal First Quarter 2023

Accolade (ACCD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Accolade (ACCD) Stock Jumps 7.2%: Will It Continue to Soar?

Accolade and Priority Health will discuss how Personalized Healthcare can deliver value for health plans seeking virtual first solutions for whole person care. SEATTLE , June 21, 2022 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD), the company that provides millions of individuals and their families with Personalized Healthcare, will be at AHIP 2022 on June 21-23 in Las Vegas, NV.

Accolade to showcase Personalized Healthcare for health plans at AHIP 2022

SEATTLE, June 21, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal first quarter 2023 financial results on Thursday, June 30, 2022, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Accolade to Announce Fiscal First Quarter 2023 Financial Results

SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the following upcoming investor conferences. A webcast and replay of each event will be available at ir.accolade.com.

Accolade Announces Participation in June Investor Conferences

NEW YORK , May 30, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Accolade, Inc. ("Accolade" or the "Company") (NASDAQ: ACCD). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Accolade, Inc. - ACCD

New York, New York--(Newsfile Corp. - May 28, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Accolade, Inc. ("Accolade" or the "Company") (NASDAQ: ACCD). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Accolade and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Accolade, Inc. - ACCD

NEW YORK , May 17, 2022 /PRNewswire/ -- WHY: New York, N.Y., May 17, 2022.

News for Accolade Stock (ACCD)